Primary tumor cells obtained from MNU-induced mammary carcinomas show immune heterogeneity which can be modulated by low-efficiency transfection of CD40L gene

被引:6
作者
Esendagli, Gunes [1 ]
Canpinar, Hande [1 ]
Yilmaz, Guldal [2 ]
Gunel-Ozcan, Aysen [3 ]
Guc, M. Oguz [4 ]
Kansu, Emin [1 ]
Guc, Dicle [1 ]
机构
[1] Hacettepe Univ, Inst Oncol, Dept Basic Oncol, TR-06100 Ankara, Turkey
[2] Ankara Univ, Fac Med, Dept Pathol, TR-06100 Ankara, Turkey
[3] Kirikkale Univ, Fac Med, Dept Med Biol & Genet, Kirikkale, Turkey
[4] Hacettepe Univ, Fac Med, Dept Pharmacol, TR-06100 Ankara, Turkey
关键词
immune heterogeneity; primary cell culture; mammary cancer; transfection; CD40; ligand; EPITHELIAL-CELLS; ANTITUMOR IMMUNITY; BREAST CARCINOMAS; DENDRITIC CELLS; LIGAND; EXPRESSION; GROWTH; CANCER; ENHANCEMENT; CD154;
D O I
10.4161/cbt.8.2.7078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The presence of CD40 on carcinoma cells is an important factor for the generation of tumor-specific responses induced by CD40 ligation. In an N-methyl-N-nitrosourea (MNU)-induced autochthonous mammary tumor model, we analyzed the immune features of primary tumor cells. Here, CD40 was frequently detected on the primary tumor cultures and selectively expressed on the malignant mammary tissue in vivo. On the other hand, every mammary tumor cell culture had a heterogeneous and reduced expression of proinflammatory TNF alpha, IL-1 beta, IL-6 and CXCL1 cytokines compared to normal mammary epithelial cells. Low-efficiency transfection of CD40 ligand (CD40L) gene enhanced the expression of proinflammatory cytokines in the tumor cells, and strengthened allogeneic immune reactions and costimulatory activity which may help overwhelming suppressive features of the tumor.
引用
收藏
页码:136 / 142
页数:7
相关论文
共 36 条
[1]  
Abbas A.K., 2003, CELLULAR MOL IMMUNOL
[2]   Role for CD40-CD40 ligand interactions in the immune response to solid tumours [J].
Alexandroff, AB ;
Jackson, AM ;
Paterson, T ;
Haley, JL ;
Ross, JA ;
Longo, DL ;
Murphy, WJ ;
James, K ;
Taub, DD .
MOLECULAR IMMUNOLOGY, 2000, 37 (09) :515-526
[3]   Tumour-induced suppression of immune response and its correction [J].
Banat, GA ;
Christ, O ;
Cochlovius, B ;
Pralle, HB ;
Zöller, M .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 49 (11) :573-586
[4]   NORMAL BREAST EPITHELIAL-CELLS PRODUCE INTERLEUKIN-6 AND INTERLEUKIN-8 TOGETHER WITH TUMOR-NECROSIS-FACTOR - DEFECTIVE IL6 EXPRESSION IN MAMMARY-CARCINOMA [J].
BASOLO, F ;
CONALDI, PG ;
FIORE, L ;
CALVO, S ;
TONIOLO, A .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (06) :926-930
[5]   Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy [J].
Brown, BD ;
Lillicrap, D .
BLOOD, 2002, 100 (04) :1133-1140
[6]  
COHEN LA, 1982, IN VITRO CELL DEV B, V18, P565
[7]   What is the real role of CD40 in cancer immunotherapy? [J].
Costello, RT ;
Gastaut, JA ;
Olive, D .
IMMUNOLOGY TODAY, 1999, 20 (11) :488-493
[8]  
Couderc B, 1998, CANCER GENE THER, V5, P163
[9]   Molecular and functional analysis of a novel recombinant clone of rat (Rattus norvegicus) CD40 ligand (CD40L) gene [J].
Esendagli, Gunes ;
Gunel-Ozcan, Aysen ;
Canpinar, Hande ;
Guc, Dicle .
MOLECULAR BIOLOGY REPORTS, 2009, 36 (01) :83-89
[10]  
FRESHNEY RI, 2002, CULTURE SPECIALIZED